Compare Global X Robo Global Robotics & Automation ETF (ROBO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robo Global Robotics & Automation ETF vs Sanofi SA — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $79.45, while Sanofi SA trades at $43.12 (market cap $103.41B). The key difference: Sanofi SA pays a 5.65% dividend while Global X Robo Global Robotics & Automation ETF pays none, and Global X Robo Global Robotics & Automation ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| ROBO | SNY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $52.34 |
52-Week Low | $63.04 | $41.33 |
Market Cap | — | $103.41B |
Enterprise Value | — | $123.44B |
Dividend Yield | — | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ROBO Global Robotics and Automation Index ETF (ROBO) trades at $79.65, down 1.14% with a bearish technical signal. The robotics ETF faces mixed momentum as moving averages indicate selling pressure while oscillators remain neutral. Recent news highlights accelerating robotics adoption across manufacturing, healthcare, and military applications, with NVIDIA's AI growth outlook providing sector tailwinds.
The ETF offers diversified exposure to robotics growth themes, though valuation metrics are unavailable. Key risks include sector concentration and AI adoption pace variability. Analyst sentiment appears cautiously optimistic given the structural growth drivers in industrial automation and physical AI applications.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
